Peroxisome proliferator-activated receptor g coactivator 1-a (PGC-1a) is a highly conserved transcriptional coactivator enriched in metabolically active tissues including liver, adipose, pancreas, and muscle. It plays a role in regulating whole body energy metabolism and its deregulation has been implicated in type 2 diabetes (T2D). A single nucleotide variant of the PPARGC1A gene (rs8192678) is associated with T2D susceptibility, relative risk of obesity and insulin resistance, and lower indices of b cell function. This common polymorphism is within a highly conserved region of the bioactive protein and leads to a single amino acid substitution (glycine 482 to serine). Its prevalence and effects on metabolic parameters appear to vary depending on factors including ethnicity and sex, suggesting important interactions between genetics and cultural/environmental factors and associated disease risk. Interestingly, carriers of the serine allele respond better to some T2D interventions, illustrating the importance of understanding functional impacts of genetic variance on PGC-1a when targeting this pathway for personalized medicine. This review summarizes a growing body of literature surrounding possible links between the PGC-1a Gly482Ser single nucleotide polymorphism and diabetes, with focus on key clinical findings, affected metabolic systems, potential molecular mechanisms, and the influence of geographical or ethnic background on associated risk. (Endocrinology 159: 853-865, 2018) 
M
etabolic diseases (including, but not limited to, cardiovascular disease, fatty liver disease, and diabetes) have long been associated with poor diet, age, and a sedentary life. Although these lifestyle factors contribute significantly to disease susceptibility and development of the metabolic syndrome, the influence of genetics is widely accepted. In type 2 diabetes (T2D), there is substantial evidence supporting the role of genetic factors in the susceptibility and pathogenesis of the disease as well as individual response to treatment. For example, there is a 40% chance of diabetes in offspring when one parent has T2D and a 70% concordance of incidence among monozygotic twins (1) compared with 10% between dizygotic twins (2) . Although these associations provide convincing evidence for our genome determining disease risk, efforts to identify the specific genes involved have proven challenging.
One approach to identify common gene variants associated with disease risk is to perform genome-wide association studies (GWAS) involving large-scale statistical analysis of single nucleotide polymorphism (SNP) enrichment in patient populations. However, for T2D, there remains a lack of agreement and certainty surrounding genetic risk markers for the disease, with ,10% of heritability currently explained by GWAS (3, 4) . To date, there are at least 80 gene variants associated with diabetes risk (5) . These discoveries significantly advanced our knowledge of genetic factors and molecular pathways influencing diabetes risk, yet major roadblocks exist in our ability to translate this knowledge from bench to bedside. Many of the known or predicted target pathways are linked to pancreatic b cell biology or insulin sensitivity, yet functional consequences of most variants have yet to be elucidated. Even in cases where the predicted gene target is clear, the basic biology of many encoded proteins is still unknown. SNP often lie in uncharacterized genomic regions or have unknown/ unpredictable effects on protein function. Each SNP in isolation has arguably minor effects on risk and proposed "genetic risk signatures" remain difficult to prove experimentally and do not appear to increase risk predictability better than traditional methods (5) . Complementary methodology involving fundamental research, clinical studies, and/or linkage analysis can also be useful to identify disease-associated genes. One target shown to be associated with diabetes using these alternative approaches is the gene encoding peroxisome proliferator-activated receptor g coactivator 1-a (PGC-1a), PPARGC1A.
Is There a Role for Genetic Variation of PPARGC1A in Metabolic Disease?
In 1998, an autosomal genomic scan of 363 nondiabetic Pima Indians was performed to uncover genetic loci linked to prediabetic traits (6) , identifying locus 4p15-q12 as associated with increased fasting insulin. This domain of human chromosome 4 contains approximately 44 known genes, including clock circadian regulator (CLOCK), huntingtin (HTT), Wolfram syndrome 1 (WFS1), and peroxisome proliferator-activated receptor gamma, coactivator 1 a (PPARGC1A). Deeper analysis of a subset of genes involved in energy metabolism revealed that a common polymorphism within the coding region of PPARGC1A (rs8192678, 1444G.A, Gly482Ser) is associated with acute measures of insulin secretion (7) . This SNP encodes a single nucleotide difference in the messenger RNA (mRNA) sequence, resulting in either a serine or a glycine amino acid residue being encoded at the 482 position of human peroxisome proliferator-activated receptor (PPAR) gamma coactivator 1-a (PGC-1a).
Around the same time, the PGC-1a protein was identified in a yeast two-hybrid screen searching for PPARg-interacting factors in brown adipose tissue (8) . PGC-1a is a large, unstructured protein with activation and transcription factor binding domains largely concentrated in its N-terminal region (9) . This transcriptional coactivator is expressed in various metabolically active tissues, including muscle, brain, adipose tissue, liver, and heart (10). In addition to PPARg, PGC-1a enhances activity of other PPARs (11, 12) and associates with various transcription factors required for oxidative metabolism, mitochondrial biogenesis, ROS homeostasis, insulin and glucagon signaling (10) . For example, in mouse muscle, PGC-1a is required to maintain expression of mitochondrial proteins required for oxidative phosphorylation and its loss leads to disrupted glucose metabolism and exercise capacity (13) . In the b cell and adipose tissue, PGC-1a is mostly dispensable for maintenance of mitochondrial genes involved in oxidative capacity, but significantly affects insulin secretion and insulin sensitivity, respectively (14) (15) (16) . These examples highlight the highly tissue-specific nature of PGC-1a function and its considerable involvement in whole-body energy metabolism.
In the years following, the importance of PGC-1a in controlling multiple aspects of mitochondrial structure and biology became well established, often leading to the protein being labeled a master regulator of mitochondrial function (17) . Soon after, a second clinical study investigating the influence of seven PGC-1a genetic variants in Danish Caucasians independently identified associations between T2D incidence and the PGC-1a Gly482Ser polymorphism (18) . With growing knowledge of its biological importance in adaptive mitochondrial metabolism, the early clinical evidence linking this PGC1a SNP to diabetes aligned well with the then emerging hypothesis that mitochondrial dysfunction could underlie diabetes pathology (19) .
Evidence Linking the PGC-1a G482S Polymorphism to Diabetes
Since the discoveries linking PGC-1a to both mitochondrial function and diabetes risk, interest in this protein and the effects of variation within its gene on metabolic health have grown. Many studies have since investigated associations between the PGC-1a 482 risk allele, T2D incidence and related disease traits. Danish Caucasians subjects with a PGC-1a 482Ser allele have significantly higher incidence of T2D compared with those with only 482Gly alleles, corresponding to a 1.34 relative risk of disease (18) . Although a second set of analyses failed to reproduce the association of the Gly482Ser SNP with T2D in Pima Indians, nondiabetic Pima Indians carrying one or two serine-containing alleles have higher insulin secretion 3 and 30 minutes following glucose infusion with equal blood glucose levels (7), suggesting increased insulin resistance. 482Ser carriers also have lower free fatty acids, smaller adipocyte size, and higher rates of lipid oxidation even in the presence of hyperinsulinemia (7) , suggesting that the serine-containing allele reduces insulin effectiveness in a potentially dominant manner. Consistently, obese Caucasians of Italian descent with a 482Ser allele have decreased insulin sensitivity [by homeostatic model assessment of insulin resistance (HOMA-IR)] and increased fasting insulin independent of age, sex, body mass index (BMI), highdensity lipoprotein-cholesterol or triglycerides, and regardless of heterozygosity or homozygosity at the gene locus (20) . Japanese subjects with one or two 482Ser-containing alleles also present with increased fasting insulin and insulin resistance following adjustment for BMI, age, and sex in a population of .900 subjects (21) .
Despite a growing number of studies showing association with disease traits, incidence of the serineencoding allele is not consistently elevated in all subjects with diabetes (22, 23) , pointing to the importance of other genetic or environmental factors influencing associated risk. Haplotypes containing the 482Ser variant and other PGC-1a polymorphisms (such as the synonymous Thr394Thr PGC-1a variant) are also significantly associated with T2D incidence (21, 24) and impaired oral glucose tolerance in offspring of subjects with T2D (25), suggesting an additive or modifying role for the Gly482Ser polymorphism on other diabetes risk alleles. The Gly482Ser PGC-1a SNP interacts with the widely known Pro12Ala PPARg diabetes-associated risk allele (26) to influence fasting and postprandial insulin, as well as HOMA-IR (27) . With PPARg as an established downstream target of PGC1a, identification of two genetic variants converging on one signaling pathways is compelling evidence for the role of altered PPAR function in diabetes pathogenesis. Accordingly, PPARg agonists (e.g., TZDs) remain some of the most highly effective insulin-sensitizing drugs, albeit their use is now limited because of side effects that include weight gain, edema, loss of bone density, increased cardiovascular risk, and possible bladder cancer (28) (29) (30) .
Other haplotypes containing the Gly482Ser of PGC1a and SNPs of PPARd, UCP1, or UCP2 confer a greater risk of diabetes or reduced responses to treatment (31) (32) (33) (34) (35) (36) . Table 1 summarizes interactions between the PGC-1a
Gly482Ser variants and other polymorphisms influencing metabolic disease. Although these observations suggest that the PGC-1a Gly482Ser SNP has a more modifying than causative role in diabetes pathogenesis, when combined with additional risk factors such as obesity, diet, and low exercise, genetic variation of this locus appears to have important implications on overall risk assessment, disease severity, and treatment strategy. Consistent with this, a study of 3244 participants aged 20 to 59 (Netherlands) shows that carriers of the 482Ser allele with BMI , 25 kg/m 2 have lower blood glucose (40) , whereas the relationship becomes inversed when BMI reaches .25 kg/m 2 and carriers of the 482Ser allele instead present with higher fasting glucose. Because overall metabolic health involves a combination of factors and organs systems, the tissuespecific function(s) of PGC-1a may be important in determining mechanisms linking this SNP to diabetes.
How Does the Gly482Ser PGC-1a Polymorphism Influence Metabolic Disease?
Adiposity and BMI
While investigating effects of metformin and lifestyle intervention on T2D in patients with high fasting glucose and impaired glucose tolerance, researchers found that the Gly482Ser PGC-1a polymorphism independently associated with increased adiposity (41) . 482Ser allele carriers have elevated baseline HOMA-IR and subcutaneous adiposity, but this association is no longer statistically significant when adjusted for BMI (41) . The serine allele is also associated with elevated body fat mass (38, 39) Phenotypes associated with genetic haplotypes containing the PPARGC1A rs8192678 SNP and other SNPs.
Abbreviations: AUC, area under the curve; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; OR, odds ratio. in Korean children (42) and in overweight, nondiabetic Chinese adults (43) . Moreover, an increase in total body fat mass, hip circumference, BMI, and body fat ratio is seen in 482Ser/482Ser homozygotes of Mexican-Mestizo descent populations (44) and excessive weight gain associates with the 482Ser allele in males with type 1 diabetes receiving intensive diabetes therapy (45) . On the contrary, there is no association between the SNP and obesity in Danish Caucasians (46) or in a population of Asian Indians (47) . In Pima Indians, nonesterified fatty acids (NEFAs) level are lower in 482Ser carriers (7), suggesting that adipose tissue lipolysis may be impaired. Obese Caucasian carriers of the 482Ser allele have reduced clearance of NEFA following oral glucose challenge (48) . Elevated postprandial NEFA can inhibit insulin signaling and glucose disposal and promote lipoprotein secretion from liver, which all contribute to T2D pathogenesis. Taken together, available data suggest that the Gly482Ser PGC-1a polymorphism negatively affects adipose tissue biology or function, and, specifically, the serine-containing allele of PGC-1a confers a higher risk of obesity in certain populations. Thus, links between this SNP and increased T2D susceptibility may simply be due to effects on adiposity, which could explain why carriers of the 482Ser allele benefit more from interventions aimed at weight loss, including caloric restriction (49), bariatric surgery (50), and acarbose treatment (32) . Serine-allele carriers are also less responsive to the beneficial effects of rosiglitazone on postprandial insulin, high-density lipoprotein, blood glucose (fasting and postprandial), and HOMA-IR (51).
Insulin sensitivity
Multiple studies show a substantial correlation between the 482Ser and indices of insulin resistance (usually HOMA-IR) in humans (20, 21, 41, 42, 49) . Insulin resistance, typically measured by the effectiveness of insulin to decrease blood glucose, is a complex pathology involving multiple tissue types and mechanisms. The role of PGC-1a in regulating the action and sensitivity of insulin in tissues is still unclear. PPARGC1A mRNA is decreased in muscle and adipose tissue of human subjects with diabetes (52) (53) (54) , and there appears to be a correlation between adipose PGC-1a protein levels and decreased insulin sensitivity (53) . Consistently, 482Ser allele carriers appear to have decreased PPARGC1A mRNA compared with Gly/Gly subjects (14) , although it is unclear how this happens. PGC-1a null mice fail to become obese on a high-fat diet, likely because of defects in the central nervous system (55, 56) . However, tissue-specific reduction of PGC-1a expression in adipose, liver, and muscle (with aging) reduce glucose tolerance and insulin sensitivity in mice (13, 16, 57, 58), supporting the hypothesis that decreased PGC-1a expression in insulinsensitive tissues may contribute to higher risk for T2D.
Insulin secretion
PGC-1a levels in the endocrine pancreas appear to directly regulate b cell function. Pancreatic islets from subjects with T2D have significantly lower PGC-1a expression and nondiabetic donor islets with a 482Ser allele (Ser/Ser or Gly/Ser) have reduced capacity to secrete insulin ex vivo in response to glucose compared with those with two 482Gly alleles (14) . In contrast, b cell function by HOMA-%B (an indirect index based on concentrations of circulating insulin and glucose) is increased in nondiabetic serine allele carriers (7, 20) , although it is not clear whether this reflects a primary effect on insulin secretion or is secondary to compensate for peripheral insulin resistance.
High levels of PGC-1a are detected in islets of Zucker diabetic fatty rats and ob/ob mice, two animal models of T2D (59) . However, overexpression of PGC-1a in mouse islets within physiological levels in vivo does not impair b cell function in adult mice (60) . b cell-specific knockout of both PGC-1a and related PGC-1b diminishes glucose stimulated insulin secretion (15) , which is consistent with data in humans (14) and implies that PGC-1a expression in the pancreatic islets directly correlates with insulin secretion (61) . Despite effects on glucose-stimulated insulin secretion, decreased PGC-1a in b cells does not affect whole body glucose tolerance in lean or obese mice (15) . Therefore, low PGC-1a in b cells may not play a predominant role in increased diabetes risk associated with gene variation, but may be additive or synergistic with effects on adiposity and insulin sensitivity in other tissues.
Cardiac and liver metabolism
In addition to T2D, the Gly482Ser polymorphism is associated with both cardiovascular disease and nonalcoholic fatty liver disease (NAFLD). There is increased risk for hypertrophic cardiomyopathy [odds ratio (OR), 1.11 to 2.11] in carriers of the 482Ser allele (62). Consistently, Mongolian carriers of the 482Ser allele have higher incidences of hypertension (63) and hypertensive patients homozygous for the serine allele have greater left ventricular hypertrophy and lower diastolic function (64) . There is also a higher incidence of the 482Ser allele among patients of Chinese descent with coronary artery disease (OR, 1.53) (65) . DNA damage (measured by 8-OHdG levels in urine) is significantly higher in Puerto Rican carriers of the serine risk allele (66) . Urinary 8-OHdG is a biomarker of general oxidative stress and is increased in hypertensive patients, but may also serve as a biomarker of cancer, atherosclerosis, and diabetes, correlating well with severity of diabetic nephropathy and retinopathy. In addition to direct effects on heart function, homozygosity of the PGC-1a 482Ser allele is also associated with increased circulating small, dense lowdensity lipoprotein particles, which are considered a predictor of coronary artery disease (67) .
Fatty liver disease increases the risk of developing T2D by two-to threefold (68) . With recent interest in metabolic liver disease as a predisposing factor to diabetes, NAFLD risk genes may also be useful in predicting diabetes risk. The PGC-1a Gly482Ser polymorphism increases risk of NAFLD in obese Taiwanese children (OR, 1.74) compared with controls homozygous for the glycine variant (38) . In obese Taiwanese adults, one serine allele is an independent risk factor for nonalcoholic steatohepatitis (NASH; a disease associated with higher steatosis and ballooning degeneration of liver cells) and carries an additive effect on NASH incidence when combined with the PNPLA3 rs738409 SNP (39) . In contrast, newly diagnosed German subjects with diabetes homozygous for the 482Gly allele have lower hepatic adenosine triphosphate, which could suggest impaired mitochondrial metabolism (69) .
Microvascular disease
If diabetes is undiagnosed or mismanaged, it can lead to several secondary complications, including eye, kidney, and nerve damage. Intriguingly, the Gly482Ser PGC-1a polymorphism may also play a role in the development of these comorbidities. In a Slovene (Caucasian) population with T2D, there is a higher frequency of the serine allele (OR, 2.7) among subjects with diabetic retinopathy (70) . The serine allele is also associated with diabetic nephropathy in Asian Indians (OR, 2.14) (71) and Koreans with T2D (72), and may increase risk for micro/ macroalbuminuria by 70% (67) . Conversely, in a Caucasian cohort from the United Kingdom, nondiabetic carriers of the serine allele appear protected against newonset diabetes following kidney transplant (OR, 0.26) (73) and the serine allele protects against T2D in subjects of Chinese descent with high levels of serum uric acid, an independent risk factor for diabetes (74, 75) .
Variables Affecting Strength of the rs8192678-Diabetes Association
Despite mounting clinical evidence and association studies, the PGC-1a Gly482Ser polymorphism has yet to be identified in GWAS for diabetes. Although largely unbiased in their design, GWAS studies have limitations. It is widely accepted that diabetes risk is influenced by ethnicity; however, GWAS for this disease are mostly limited to Caucasian populations of European descent or Asian populations of Japanese or Chinese descent (5). More recent efforts incorporating multiethnic analyses have confirmed many of the previously identified genes and identified candidates that appear specific for certain genetic backgrounds (22) . Unfortunately, the goal to identify genes influencing worldwide diabetes risk often leads to variants found only in specific populations being ignored or undervalued. The influence of sex on diabetes risk is also well established in the clinic, with males being more susceptible than women (before menopause); however, for the most part, males and females are grouped together in these large-scale genomic analyses. Finally, we are only beginning to appreciate the possible implications of geographical, cultural, environmental, or even sociological influence on the genetic basis of the disease, and these are rarely considered in GWAS. In the age of personalized medicine, understanding the biological implications of identified gene variants and how they are influenced by environment may prove more valuable than generalized lists of "risk" vs "protective" genes.
The influence of sex on PGC-1a and the Gly482Ser polymorphism
Accumulating evidence suggests PGC-1a expression and activity may be significantly influenced by sex. The 482Ser allele is associated with reduced risk of diastolic dysfunction (OR, 0.13 to 0.19) in Swedish men (76) , but no effect is observed in women. In contrast, a substantial increase in arterial hypertension prevalence is reported only for male French Caucasians with a 482Ser allele (77) . In Japanese males with T2D, having one or two 482Ser alleles lowers circulating adiponectin (an antidiabetic adipokine), whereas PPARGC1A SNP genotype has no influence on adiponectin concentrations in females. In contrast, only 482Ser/482Ser Japanese women trend toward having higher fasting plasma glucose (78) . Although seemingly contradictory results are presented (protective vs detrimental effects of variant; varying influences of sex), it is interesting to note that that the French and Japanese subjects also had T2D, again suggesting that additional lifestyle and genetic factors play a modifying role in PGC-1a activity. In support of this, sedentary Swedish males carrying a 482Ser allele have a greater risk of developing obesity with age; but again, no association with obesity, age, or activity is reported for Swedish females (79) . Thus, there is compelling evidence that sex has an important effect on the outcome of this SNP on metabolic disease, often having more substantial outcomes in one sex over another and influenced by environmental factors such as activity, diet, and age.
Although clear metabolic differences in clinical studies suggest that sex is an important factor influencing PGC1a activity, very few studies attempt to explain the sexually dimorphic metabolic phenotypes. A possible explanation comes from recent evidence in mouse liver and brain suggesting that PGC-1a expression is regulated by sex hormone signaling, and that the coactivator directly interacts with sex hormone receptors to augment their activity. In the brain, female mice have lower markers of hypothalamic inflammation in response to a high-fat diet. It was found that this phenomenon could be linked to the anti-inflammatory properties of PGC-1a and ERa in the female brain (80) . Our laboratory demonstrated that PGC-1a is particularly important for ROS detoxification and protection from NASH in female mice. In the presence of estrogen, PGC-1a coactivates ERa to enhance hepatic mitochondrial ROS defenses in response to diets high in fat and fructose (57) . In addition, estrogen promotes PGC-1a expression in hepatocytes in a PGC-1a-dependent manner, feeding forward to amplify ROS-detoxifying pathways. This feed forward mechanism involving estrogen is consistent with female mice having three-to fourfold higher levels of the coactivator in liver than male littermates. Given the importance of PGC-1a activity on estrogen's protective effects in liver, female mice are much more susceptible to obesity-induced oxidative damage when PGC-1a activity is reduced (57) .
Selective pressure and ethnicity
The PGC-1a protein, and the domain containing the Gly482Ser SNP in particular, are highly conserved across species (81) . Interestingly, although the serine containing allele is arguably the "minor allele" in many human populations (81) , most other vertebrates have a serine in this position. Searching available databases, we and others (81) have found only humans (Homo sapiens), chickens (Gallus gallus), and wild turkeys (Meleagris gallopavo) to have a glycine-containing allele; however, many species of birds (e.g., Columba livia, or rock pigeon) and the fruit bat (Rousettus aegyptiacus) alternatively have an arginine (R) residue. These limited data suggest the glycine-containing variant may have appeared later in evolution and became enriched in humans from selective pressure, or it was selected against in other species. A higher than expected prevalence of 482Gly/482Gly genotype might also suggest that this allele provides selective advantage to certain groups of people. However, if the 482Ser variant is truly a strong risk allele for metabolic disease in humans, why does this variant remain so prevalent in humans, and why is it not selected against in other species?
A plausible explanation might be that the onset of metabolic disease often occurs years after reproductive age, providing no resistance to the allele being passed to future progeny. However, if the SNP has no influence before disease onset, one would expect classical Mendelian ratios of SNP prevalence, which is not the case in most populations tested. The majority of published clinical studies on this SNP were performed in subjects of European descent, where the prevalence of the 482Gly/ 482Gly phenotype averages around 50%, with 482Ser/ 482Ser homozygotes detected at rates of 10% to 15% (82) . Interestingly, the prevalence of each variant seems to vary greatly depending on geographical location (83) . Sampling data suggest that 482Ser "risk" allele prevalence can reach .80% in some Polynesian island nations of the South Pacific, whereas many areas within Africa, Papua New Guinea, and Indonesia have frequencies ,3% (based on data from the Human Genome Diversity Cell Line Panel) (83) . These large variant frequency differences between populations led to a theory that the 482Ser allele may be considered a "thrifty gene," providing advantages to species who depend on fat storage capacity for survival (e.g., during periods of famine in both humans and rodents or hibernation in rodents) (83) . However, in times of relative food abundance, having the serine variant may promote obesity and increase metabolic disease prevalence. Recently, this hypothesis was challenged, as statistical testing did not find evidence for departure from natural evolution for this locus in a range of Polynesian, Asian, European, or African populations (84) . Additional evidence against the thrifty gene hypothesis comes from the fact that relative risk of T2D associated with the 482Ser allele is not the same across populations of humans that are now exposed to relatively similar diets and lifestyles.
This brings into question whether ethnicity plays a role in disease risk through interactions between this SNP and other disease-modifying genes or environmental factors. In Caucasian populations the risk of T2D is only modestly increased by the PGC-1a Gly482Ser SNP (i.e., OR, 1.1 to 1.8), whereas OR for T2D risk increase greatly in 482Ser carrying subjects of Northern Indian (OR, 2.04 to 3.19), Iranian (OR, 9.0), Chinese (OR, 1.64 to 1.85), and Tunisian descent (OR 1.17 to 2.98) (36, (85) (86) (87) (88) . Thus, it is plausible that differences in disease risk between ethnicities linked to this polymorphism are due to additive or synergistic effects with other genetic modifiers or environmental factors specific to geographical region. Table 2 summarizes clinical data concerning effect(s) of the rs8192678 SNP and T2D risk or other risk factors of metabolic disease, including ethnicity.
How Does the Polymorphism Affect PGC-1a Structure and Function?
Now, almost 20 years later, the functional role of PGC1a in cells has expanded greatly, yet it arguably remains an essential regulator of mitochondrial function and energy metabolism. PGC-1a transcription, protein stability, and activity are very precisely controlled. PGC-1a expression levels change rapidly in response to physiological stressors or increased energy demand (such as cold, exercise, fasting, and inflammation) (97) and the protein is quickly degraded (98) . Influences of external stimuli on PGC-1a activity, mechanisms controlling mRNA transcription and protein stability are also tissue-specific (17, (99) (100) (101) .
PPARGC1A promoter methylation correlating with reduced PGC-1a gene expression is also implicated in T2D (14, 102, 103) . For example, in human diabetic islets, there is a twofold increase in DNA methylation compared with islets from patients without diabetes (14) . Additionally, PGC-1a promoter methylation is negatively correlated with PPARGC1A gene expression and mitochondrial number in skeletal muscle from T2D subjects (103) . Blood glucose levels following glucose challenge in women with gestational diabetes correlate with placental PPARGC1A promoter methylation (104) . In mice, maternal obesity linked to high fat and sugars diets is associated with hypermethylation of the Ppargc1a promoter in muscle of offspring, but this can be reversed with exercise (105) . Although these studies collectively show that epigenetic regulation of PPARGC1A correlates with reduced PGC-1a expression and diabetes pathogenesis, it remains unclear whether increased promoter methylation is a cause or consequence of obesity and/or T2D development.
An additional level of complexity in PGC-1a regulation is added by extensive posttranslational modification. Phosphorylation, acetylation, ubiquitination, and methylation all affect PGC-1a stability and activity (17) . For example, phosphorylation by Akt at 570Ser enhances PGC-1a activity (106) , whereas Clk2 phosphorylation of serine residues in the SR region (spanning residues 564-635) decreases coactivator function (17, 107) . There are also phosphorylation events that target PGC-1a for ubiquitination and proteosomal degradation, thereby affecting protein stability (108) . Although several PGC1a posttranslational modifications are identified, many remain uncharacterized and downstream consequences of many modifications on metabolism are unclear.
Lower PGC-1a expression is commonly associated with poor health outcomes (109) , and lower PGC-1a mRNA expression is found in muscle (110) and islets (14) of serine allele carriers with T2D. These studies provided evidence suggesting that a serine at position 482 may reduce PGC-1a levels. Yet, despite clear associations of 482Ser with low PGC-1a expression, it is not clear how this occurs at the molecular level or whether the polymorphism also affects coactivator activity as well as protein level. In vitro analyses show no differences in the ability of the 482Gly and 482Ser variants to induce adiponectin promoter activity following ectopic expression in HeLa cells to equal protein levels (78) and equivalent coactivator activity for the variants is also demonstrated on the ACBP-1C promoter in HepG2 cells (111) . These two studies suggest that the polymorphism may not have direct effects on the coactivator function of PGC-1a. However, three other studies show that activity of the 482Ser variant is reduced on PEPCK and CPT1a promoters and gene targets regulating ROS detoxification in HepG2 cells (54, 112) , and increased compared with the 482Gly variant on the TFAM promoter in HeLa cells (113) (Table 3 ). Thus, cell environment as well as the gene target may be determining factors for observed differences in variant activity.
Another explanation for lower PGC-1a expression and activity in 482Ser carriers is that the amino acid substitution directs or disrupts protein stability. We have shown that the half-life of the 482Ser variant is shorter than the 482Gly variant in cultured liver cells, corresponding with reduced coactivator activity on target genes involved in ROS detoxification (57) . If in fact the polymorphism affects only protein degradation pathways, this would explain why coactivator function is similar for the variants when expressed to equal protein levels. It may also explain why carriers of the 482Ser allele have lower PGC-1a mRNA, because PGC-1a feeds back to increase its own expression (114) , and, over the long term, expression of a more unstable variant (482Ser) could lead to chronically lower levels.
An interesting finding drawn from clinical data is that risk associated with the 482Ser allele is not dosedependent; in most cases, the OR is similar whether the carrier has one or two serine-containing alleles. To our knowledge, this phenomenon has not been explored at molecular or mechanistic levels, but implies that the 482Ser may have a dominant role on the associated phenotypes (14, 21, 88) . However, because most clinical studies group 482Ser/482Gly and 482Ser/482Ser carriers together (possibly for power/statistical purposes), it is impossible to make conclusions from existing data sets and further experimental testing is needed.
Conclusions
Taken together, there is evidence to suggest that there is an explicit link between the Gly482Ser polymorphism and metabolic syndrome; however, there is a lack of consensus on why the "protective" allele is not more prevalent, whether other genetic and environmental factors strongly influence associated risk, and how allelic variation affects PGC-1a activity. Presently, many studies support the notion that a 482Ser variant increases the likelihood of insulin resistance, b cell dysfunction, and Summary of in vitro studies assessing functional differences between the two variants of human PGC-1a associated with the rs8192678 SNP in cell lines. The cell lines and promoter/gene target evaluated are listed, alongside any differences in activity observed in each system. doi: 10.1210/en.2017-00872 https://academic.oup.com/endo
